Metacrine, Inc.: Nasdaq/NYSE listing notice — Metacrine to be delisted from Nasdaq on March 13, 2023; trading moves to OTC

Metacrine, Inc.

Nasdaq notified Metacrine on Feb 27, 2023 of delisting; Form 25 filed March 3, 2023.
Delisting effective March 13, 2023; stock suspended from Nasdaq since Feb 9, 2023 for bid price non-compliance.
Common stock now quoted on OTC marketplace under symbol MTCR.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Metacrine, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

e filing of the Form 25. As previously disclosed, the Common Stock was suspended from trading on The Nasdaq Capital Market at the opening of business on February 9, 2023 as a result of the Company’s failure to regain compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1), and has since been quoted on the OTC marketplace under the symbol “MTCR.” Quotes and related Company information are available at www.otcmarkets.com . SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-060202

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.